Results 271 to 280 of about 63,982 (290)
Some of the next articles are maybe not open access.

Review: Cardiopulmonary Toxicity of Adoptive Immunotherapy

The American Journal of the Medical Sciences, 1988
Adoptive immunotherapy, the administration of interleukin-2 (IL-2) and interleukin-2 activated cells, leads to tumor regression in some patients with advanced cancer. Although this new therapeutic modality offers hope for the future, at present, a multitude of toxicities limit the total dose and duration of therapy.
Alpha A. Fowler   +5 more
openaire   +2 more sources

Adoptive Immunotherapy of Ovarian Carcinoma

Gynecologic Oncology, 2002
SCOPUS: le.j ; info:eu-repo/semantics ...
de Gramont, Aimery   +5 more
openaire   +2 more sources

NK cell adoptive immunotherapy

Blood, 2005
Comment on Miller et al, page [3051][1] In this issue of Blood, Miller and colleagues present data on the administration of haploidentical NK cells to cancer patients. They identify a feasible and safe method for in vivo NK cell expansion and clinical efficacy.
openaire   +4 more sources

An artificial solution for adoptive immunotherapy

Trends in Biotechnology, 2003
Abstract Adoptive immunotherapy is a promising strategy in the battle against cancer and infectious diseases and the recently developed artificial antigen-presenting cell (aAPC) overcomes several obstacles for this therapy. The aAPC recapitulates the natural in vivo antigen-presenting cell (APC)–T cell interactions by coupling human leukocyte ...
openaire   +3 more sources

Adoptive T‐cell transfer in cancer immunotherapy

Immunology & Cell Biology, 2006
Adoptive T‐cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein–Barr virus‐associated post‐transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self‐antigens and success has been limited in part by inadequate persistence and expansion of transferred
Tey, Siok-Keen   +2 more
openaire   +4 more sources

Adoptive T cell immunotherapy for cytomegalovirus

Expert Opinion on Biological Therapy, 2009
Cytomegalovirus (CMV) is a major opportunistic pathogen following allogeneic transplantation, reflecting the inability of depressed host immunity to contain viral replication. Current antiviral drugs are limited by toxicities and lack of efficacy in established CMV disease, making adoptive immunotherapeutic strategies aimed at hastening virus-specific ...
openaire   +3 more sources

CASE FOR ADOPTIVE IMMUNOTHERAPY IN CANCER

The Lancet, 1982
Patients with normal immune systems may be unable to mount effective defences against solid tumours because of (1) the generation of suppressor T cells in the low zone tolerance response elicited by the low concentrations of antigen furnished by slow growing solid tumours; (2) the ineffectiveness of the cytolytic T-cell response when the tumour cell ...
openaire   +3 more sources

ADOPTIVE IMMUNOTHERAPY

The Pediatric Infectious Disease Journal, 1999
J L, Hurwitz, K S, Slobod
openaire   +2 more sources

Adoptive Immunotherapy

2008
Chrystal U. Louis, Helen E. Heslop
openaire   +1 more source

Home - About - Disclaimer - Privacy